NCM
GPCR icon

NEXTBio Capital Management’s Structure Therapeutics GPCR Stock Holding History

NEXTBio Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.8M Buy
312,496
+179,257
+135% +$7.93M 7.71% 4
2026
Q1 		$6.42M Buy
133,239
+38,796
+41% +$2.66M 2.98% 14
2025
Q4 		$6.57M Buy
+94,443
New +$3.86M 3.85% 10

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

NEXTBio Capital Management's GPCR Position: Q2 2026 in Review

NEXTBio Capital Management increased its Structure Therapeutics (GPCR) stake by 135% in Q2 2026, buying an estimated $7.93M and bringing the position to 312,496 shares worth $16.8M. The position accounts for 7.71% of the portfolio, ranked #4.

NEXTBio Capital Management first reported a position in GPCR in Q4 2025 and has held it in 3 quarters since. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • NEXTBio Capital Management held 312,496 shares of Structure Therapeutics worth $16.8M as of Q2 2026.
  • NEXTBio Capital Management bought 179,257 Structure Therapeutics shares in Q2 2026, an estimated $7.93M.
  • Structure Therapeutics made up 7.71% of NEXTBio Capital Management's portfolio in Q2 2026, its #4 holding.
  • NEXTBio Capital Management first reported a position in Structure Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on NEXTBio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.